<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In recent experimental studies, we demonstrated a highly beneficial neuroprotective effect of moderate- to high-dose human albumin treatment of transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, but we did not define the effect of albumin therapy in permanent focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, anesthetized Sprague-Dawley rats were subjected to permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> by retrograde insertion of an intraluminal nylon suture coated with poly-<z:chebi fb="0" ids="18019,29967">L-lysine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Albumin was administered i.v. at 2 h after <z:hpo ids='HP_0003674'>onset</z:hpo> of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, in doses of either 1.25 (n=8) or 2.5 g/kg (n=6) </plain></SENT>
<SENT sid="3" pm="."><plain>In a separate group of animals, albumin (2.5 g/kg) was given 1 h after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (n=6) </plain></SENT>
<SENT sid="4" pm="."><plain>Vehicle-treated rats (n=6) received 0.9% saline in equivalent volumes </plain></SENT>
<SENT sid="5" pm="."><plain>Neurological status was evaluated during and 24 h after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>One day after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes and <z:hpo ids='HP_0002181'>brain edema</z:hpo> were determined </plain></SENT>
<SENT sid="7" pm="."><plain>In a separate group of animals, cortical perfusion was assessed by Laser-Doppler perfusion imaging </plain></SENT>
<SENT sid="8" pm="."><plain>Albumin (1.25 g/kg; n=3) or vehicle (<z:chebi fb="40" ids="26710">sodium chloride</z:chebi> 0.9%; n=3) was administered at 2 h after <z:hpo ids='HP_0003674'>onset</z:hpo> of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>Higher-dose albumin therapy (2.5 g/kg) significantly improved the neurological score compared to vehicle rats at 24 h, when administered at either 1 or 2 h after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Total <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was reduced by albumin (2.5 g/kg given at 2 h) by 32% compared with vehicle-treated rats </plain></SENT>
<SENT sid="11" pm="."><plain>Both albumin doses (1.25 and 2.5 g/kg) significantly reduced cortical and striatal <z:mpath ids='MPATH_124'>infarct</z:mpath> areas at several coronal levels when administered at 2 h after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain><z:e sem="disease" ids="C1527311" disease_type="Disease or Syndrome" abbrv="">Brain swelling</z:e> was not affected by albumin treatment </plain></SENT>
<SENT sid="13" pm="."><plain>Cortical perfusion declined during middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in both groups </plain></SENT>
<SENT sid="14" pm="."><plain>Treatment with albumin led to 48% increases in cortical perfusion (P&lt;0.002), but saline caused no change </plain></SENT>
<SENT sid="15" pm="."><plain>These results support a beneficial effect of albumin therapy in permanent focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>